ECO Animal Health Group (EAH) Fair Value & Analysis
Healthcare · GB · Market cap 63.7M GBX
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price −7.9% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.5700 – £1.14 · fair‑value band £0.9000 – £1.40 · the £0.8800 price screens below the £1.15 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ECO Animal Health Group (EAH) currently trades at £0.8800, while our model-based Fair Value estimate is £1.15 — implying the stock looks roughly 30.7% undervalued today. We read business quality at 84/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, ECO Animal Health Group generated revenue of £85.8M at a net margin of 3.5%. Revenue grew 18.7% year over year. It earns a return on equity of 5.6%. The balance sheet holds a net cash position of £21.2M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
ECO Animal Health Group plc, together with its subsidiaries, manufactured and supply animal health products internationally. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. ECO Animal Health Group plc was founded in 1972 and is based in London, the United Kingdom.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ECO Animal Health Group reported revenue of £79.6M in FY2025 versus £106M in FY2021, a compound −6.8%/yr. Reported net income was £1.7M in FY2025, compounding −30.8%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ECO Animal Health Group (EAH) undervalued?
What is the fair value of EAH?
What is the quality score of EAH?
What is the revenue of ECO Animal Health Group (EAH)?
What is the net profit margin of EAH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.